Dupixent Lawsuits

People are filing Dupixent (dupilumab) lawsuits because the medication may increase the risk of cutaneous T-cell lymphoma (CTCL). CTCL is a rare type of cancer that affects white blood cells.

Lawsuits allege that drugmakers Regeneron Pharmaceuticals and Sanofi Genzyme didn’t properly warn patients and doctors about the cancer risk.

A recent study published in the European Respiratory Journal found that asthma patients who took Dupixent had a 79% higher risk of lymphoma, and a 4.5-fold increased risk of T and natural killer cell lymphomas.

According to a 2024 study in Dermatologic Therapy, Dupixent users are at risk for developing CTCL. Most Dupixent patients who developed CTCL were diagnosed within the first year. The risk was also higher in patients over the age of 60.

In addition to an increased risk of CTCL, studies suggest that Dupixent may worsen CTCL in people who already have the disease.

Warning Signs of CTCL

CTCL usually appears as a rash or scaly patches on the skin. However, it’s not actually skin cancer. It’s a type of non-Hodgkin lymphoma that usually grows slowly and impacts the skin, but can enter the blood or spread to lymph nodes.

Mycosis fungoides and Sézary syndrome are the most common types of CTCL. Comprising 60% to 70% of CTCL cases, mycosis fungoides usually starts as a skin rash. Sézary syndrome is less common and affects your blood and skin.

You may qualify for a Dupixent lawsuit if you took the medication and developed CTCL. Each law firm may have slightly different eligibility criteria, but most have the same basic requirements.

If you took Dupixent and were diagnosed with CTCL, you should contact a lawyer. They can verify whether or not you have a case.

Make sure to have any receipts, medical records and physician notes handy when you talk with an attorney. They will ask you questions about your Dupixent experience and CTCL diagnosis to determine your eligibility to file a lawsuit.

Dupixent litigation is in the early stages. There haven’t been any settlements or trials yet. There is no Dupixent class action, and lawyers expect cases to proceed individually.

However, if there are enough cases, they could be consolidated into multidistrict litigation (MDL). MDLs combine multiple similar cases to streamline the legal process.

The first step in filing a Dupixent lawsuit is to sign up for a free case review on Drugwatch. We can connect you with an experienced lawyer so you can focus on your medical treatment and recovery.

Getting a case review is free, and there’s no upfront cost to file a lawsuit. In product liability cases, like a Dupixent cancer claim, most lawyers only get paid if they win your case.

There haven’t been any Dupixent settlement amounts yet. Since there haven’t been any jury verdicts, it’s difficult to estimate what a Dupixent lawsuit is worth.

In other product liability cancer cases, like hair relaxer uterine cancer cases, lawyers estimate that settlement amounts range from $100,000 to $2 million.

Each case is different, and the value of a case may depend on the severity of a plaintiff’s CTCL. Settlement amounts may take into account the cost of treatment, lost wages, decreased quality of life and other damages.